JP4647909B2 - 大うつ病性障害の治療における（１１β，１７β）−１１−（１，３−ベンゾジオキソール−５−イル）−１７−ヒドロキシ−１７−（１−プロピニル）エストラ−４，９−ジエン−３−オンの使用 - Google Patents

大うつ病性障害の治療における（１１β，１７β）−１１−（１，３−ベンゾジオキソール−５−イル）−１７−ヒドロキシ−１７−（１−プロピニル）エストラ−４，９−ジエン−３−オンの使用 Download PDF

Info

Publication number
JP4647909B2
JP4647909B2 JP2003539697A JP2003539697A JP4647909B2 JP 4647909 B2 JP4647909 B2 JP 4647909B2 JP 2003539697 A JP2003539697 A JP 2003539697A JP 2003539697 A JP2003539697 A JP 2003539697A JP 4647909 B2 JP4647909 B2 JP 4647909B2
Authority
JP
Japan
Prior art keywords
treatment
patients
propynyl
hydroxy
benzodioxol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003539697A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005521637A5 (https=
JP2005521637A (ja
Inventor
セネフ，コルネリス
ペータース，ベルナルドス・ウエイナンド・マテイス・マリー
Original Assignee
ナームローゼ・フエンノートチヤツプ・オルガノン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナームローゼ・フエンノートチヤツプ・オルガノン filed Critical ナームローゼ・フエンノートチヤツプ・オルガノン
Publication of JP2005521637A publication Critical patent/JP2005521637A/ja
Publication of JP2005521637A5 publication Critical patent/JP2005521637A5/ja
Application granted granted Critical
Publication of JP4647909B2 publication Critical patent/JP4647909B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2003539697A 2001-10-26 2002-10-21 大うつ病性障害の治療における（１１β，１７β）−１１−（１，３−ベンゾジオキソール−５−イル）−１７−ヒドロキシ−１７−（１−プロピニル）エストラ−４，９−ジエン−３−オンの使用 Expired - Fee Related JP4647909B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01204072 2001-10-26
PCT/EP2002/011732 WO2003037354A1 (en) 2001-10-26 2002-10-21 USE OF (11β, 17β)-11-(1,3-BENZODIOXOL-5-YL)-17-HYDROXY-17-(1-PROPYNYL)-ESTRA-4,9-DIEN-3-ONE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER

Publications (3)

Publication Number Publication Date
JP2005521637A JP2005521637A (ja) 2005-07-21
JP2005521637A5 JP2005521637A5 (https=) 2006-01-05
JP4647909B2 true JP4647909B2 (ja) 2011-03-09

Family

ID=8181136

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003539697A Expired - Fee Related JP4647909B2 (ja) 2001-10-26 2002-10-21 大うつ病性障害の治療における（１１β，１７β）−１１−（１，３−ベンゾジオキソール−５−イル）−１７−ヒドロキシ−１７−（１−プロピニル）エストラ−４，９−ジエン−３−オンの使用

Country Status (26)

Country Link
US (1) US20040266863A1 (https=)
EP (2) EP1652526B1 (https=)
JP (1) JP4647909B2 (https=)
KR (1) KR20050038580A (https=)
CN (1) CN100531738C (https=)
AT (2) ATE317700T1 (https=)
AU (1) AU2002348996B2 (https=)
BR (1) BR0213466A (https=)
CA (1) CA2463446C (https=)
CY (1) CY1110173T1 (https=)
DE (2) DE60230936D1 (https=)
DK (1) DK1652526T3 (https=)
EC (1) ECSP045080A (https=)
ES (1) ES2319563T3 (https=)
HR (1) HRP20040370B1 (https=)
HU (1) HUP0500070A3 (https=)
IL (2) IL161248A0 (https=)
IS (1) IS2702B (https=)
MX (1) MXPA04003781A (https=)
NO (1) NO332978B1 (https=)
NZ (1) NZ532429A (https=)
PL (1) PL206687B1 (https=)
PT (1) PT1652526E (https=)
RU (1) RU2302245C2 (https=)
WO (1) WO2003037354A1 (https=)
ZA (1) ZA200403088B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050080061A1 (en) * 2003-07-23 2005-04-14 Corcept Therapeutics, Inc. Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
EP2292269A3 (en) * 2004-11-19 2011-08-10 N.V. Organon Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
AU2011236053B2 (en) * 2004-11-19 2014-06-26 Merck Sharpe & Dohme B.V. Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
JP2009535430A (ja) * 2006-05-02 2009-10-01 コーセプト セラピューティクス， インコーポレイテッド Ｉｌ−２を摂取している患者における抑うつを処置するためのグルココルチコイドレセプターｉｉアンタゴニストの使用
EP2671086B1 (en) * 2011-02-03 2018-04-25 Pop Test Oncology LLC System and method for diagnosis and treatment
US20120263660A1 (en) * 2011-04-18 2012-10-18 Pop Test Cortisol Llc Hair Loss Treatment
US8986677B2 (en) * 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814333A (en) * 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
DE4447401A1 (de) * 1994-12-23 1996-07-04 Schering Ag 14,17-C¶2¶-überbrückte Steroide
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
DE19727772A1 (de) * 1997-06-30 1999-01-28 Forschungszentrum Juelich Gmbh Magnetflußsensor mit ringförmiger Sonde
ATE332696T1 (de) * 1997-10-06 2006-08-15 Univ Leland Stanford Junior Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen
CN1820756A (zh) * 2001-03-23 2006-08-23 科塞普特治疗公司 使用糖皮质激素受体特效拮抗剂治疗压力症的方法
DE60238671D1 (de) * 2001-05-04 2011-02-03 Corcept Therapeutics Inc Verwendung von glucocorticoid-rezeptor-spezifischen antagonisten zur behandlung von delirium
IL160649A0 (en) * 2001-08-31 2004-07-25 Corcept Therapeutics Inc Methods for inhibiting cognitive deterioration in adults with down syndrome

Also Published As

Publication number Publication date
CA2463446C (en) 2010-02-23
EP1441739B1 (en) 2006-02-15
IL161248A (en) 2010-12-30
NO332978B1 (no) 2013-02-11
EP1652526A2 (en) 2006-05-03
US20040266863A1 (en) 2004-12-30
WO2003037354A1 (en) 2003-05-08
EP1652526A3 (en) 2006-08-02
DE60230936D1 (de) 2009-03-05
HUP0500070A2 (hu) 2005-04-28
ECSP045080A (es) 2004-06-28
PT1652526E (pt) 2009-02-06
ZA200403088B (en) 2005-01-24
NO20041651L (no) 2004-04-23
RU2302245C2 (ru) 2007-07-10
CN100531738C (zh) 2009-08-26
BR0213466A (pt) 2004-11-09
IS7204A (is) 2004-03-31
ATE420649T1 (de) 2009-01-15
CA2463446A1 (en) 2003-05-08
CY1110173T1 (el) 2015-01-14
JP2005521637A (ja) 2005-07-21
HRP20040370A2 (en) 2004-08-31
EP1652526B1 (en) 2009-01-14
KR20050038580A (ko) 2005-04-27
HUP0500070A3 (en) 2012-09-28
PL206687B1 (pl) 2010-09-30
HRP20040370B1 (hr) 2012-09-30
CN1582153A (zh) 2005-02-16
NZ532429A (en) 2004-10-29
ATE317700T1 (de) 2006-03-15
IS2702B (is) 2010-11-15
DK1652526T3 (da) 2009-05-18
ES2319563T3 (es) 2009-05-08
IL161248A0 (en) 2004-09-27
HK1087357A1 (en) 2006-10-13
EP1441739A1 (en) 2004-08-04
PL369261A1 (en) 2005-04-18
AU2002348996B2 (en) 2008-06-05
DE60209248D1 (de) 2006-04-20
RU2004116082A (ru) 2005-05-10
MXPA04003781A (es) 2004-07-30

Similar Documents

Publication Publication Date Title
EP3263112B1 (en) Compositions and methods for suppressing endometrial proliferations
US7361646B2 (en) Methods for treating gastroesophageal reflux disease
JP4647909B2 (ja) 大うつ病性障害の治療における（１１β，１７β）−１１−（１，３−ベンゾジオキソール−５−イル）−１７−ヒドロキシ−１７−（１−プロピニル）エストラ−４，９−ジエン−３−オンの使用
US8193172B2 (en) Methods for the treatment of major depressive disorder using glucocorticoid receptor antagonists
AU2002348996A1 (en) Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatement of major depressive disorder
HK1087357B (en) Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder
WO2009061569A1 (en) Compositions and methods for treating dysfunctional uterine bleeding

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051017

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20070416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090302

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100721

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101027

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101122

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101209

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131217

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131217

Year of fee payment: 3

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131217

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees